ATNM
AMEX
$0.88
Actinium Pharmaceuticals Inc (ATNM)
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of cell therapy, and for other adoptive cell therapies. The company is headquartered in New York, New York.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $5 (+466.19%)
Market Cap
$29M
Free Cash Flow Yield
-80.47%
Beta (5Y)
1.57
Price Chart
Valuation
Market Cap$29M
Forward P/E6.84
P/S320.69
P/B12.19
Profitability
Total Revenue (TTM)$90K
Gross Profit (TTM)$90K
EBITDA-$25M
Operating Margin-28347%
EPS-$0.75
Financial Health
Free Cash Flow Yield-80.47%
Growth & Risk
EPS 5Y CAGR-11.69%
Revenue 5Y CAGR-32.07%
FCF 5Y CAGR+1.19%
Beta (5Y)1.57
Sharpe Ratio-0.71